RJK-RT2831
/ RegeneCore Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 08, 2025
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
(clinicaltrials.gov)
- P1 | N=71 | Recruiting | Sponsor: Nanjing RegeneCore Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Oncology
April 02, 2025
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
(clinicaltrials.gov)
- P1 | N=71 | Not yet recruiting | Sponsor: Nanjing RegeneCore Biotech Co., Ltd. | Initiation date: Dec 2024 ➔ Mar 2025
Trial initiation date • Hematological Disorders • Hematological Malignancies • Oncology
1 to 2
Of
2
Go to page
1